Michael Schmidt
Stock Analyst at Guggenheim
(3.66)
# 895
Out of 4,413 analysts
51
Total ratings
48.94%
Success rate
7.33%
Average return
Main Sectors:
Top Industries:
27 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DCPH Deciphera Pharmaceuticals | Downgrades: Neutral | n/a | $25.27 | - | 2 | Apr 30, 2024 | |
| IMCR Immunocore Holdings | Reiterates: Buy | $92 | $59.08 | +55.72% | 2 | Apr 23, 2024 | |
| IMNM Immunome | Initiates: Buy | $35 | $14.06 | +148.93% | 1 | Apr 15, 2024 | |
| ADCT ADC Therapeutics | Reiterates: Buy | n/a | $4.41 | - | 2 | Apr 5, 2024 | |
| IMRX Immuneering | Downgrades: Neutral | n/a | $1.42 | - | 2 | Mar 14, 2024 | |
| MRSN Mersana Therapeutics | Upgrades: Buy | $7 | $3.17 | +120.82% | 2 | Feb 29, 2024 | |
| BGNE BeiGene | Maintains: Buy | $350 → $345 | $153.94 | +124.11% | 4 | Feb 27, 2024 | |
| ALLO Allogene Therapeutics | Downgrades: Neutral | n/a | $2.76 | - | 1 | Jan 5, 2024 | |
| INCY Incyte | Upgrades: Buy | n/a | $52.05 | - | 3 | Dec 4, 2023 | |
| XNCR Xencor | Maintains: Buy | $40 → $34 | $20.94 | +62.37% | 2 | Nov 8, 2023 | |
| EXEL Exelixis | Reiterates: Buy | $30 | $23.46 | +27.88% | 3 | Oct 11, 2023 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $40 → $42 | $21.13 | +98.77% | 2 | Jul 25, 2023 | |
| ACET Adicet Bio | Downgrades: Neutral | $20 | $1.49 | +1,242.28% | 3 | Jun 27, 2023 | |
| BPMC Blueprint Medicines | Maintains: Buy | $78 → $82 | $91.34 | -10.23% | 1 | May 23, 2023 | |
| ORIC ORIC Pharmaceuticals | Downgrades: Neutral | $15 | $8.83 | +69.88% | 2 | Mar 21, 2023 | |
| ARVN Arvinas | Downgrades: Neutral | n/a | $31.77 | - | 1 | Jan 12, 2023 | |
| ADAP Adaptimmune Therapeutics | Upgrades: Buy | $5 | $1.19 | +320.17% | 1 | Jan 3, 2023 | |
| ZNTL Zentalis Pharmaceuticals | Maintains: Buy | $55 → $28 | $11.06 | +153.16% | 2 | Nov 11, 2022 | |
| GMAB Genmab | Downgrades: Neutral | n/a | $27.69 | - | 1 | Jan 3, 2022 | |
| ERAS Erasca | Initiates: Buy | n/a | $2.01 | - | 1 | Aug 10, 2021 | |
| CLLS Cellectis | Downgrades: Neutral | n/a | $2.56 | - | 1 | Apr 28, 2021 | |
| BOLT Bolt Biotherapeutics | Initiates: Buy | n/a | $1.11 | - | 1 | Mar 2, 2021 | |
| RVMD Revolution Medicines | Initiates: Buy | n/a | $37.28 | - | 1 | Mar 9, 2020 | |
| BLUE bluebird bio | Downgrades: Market Perform | n/a | $0.89 | - | 3 | Mar 5, 2019 | |
| AGIO Agios Pharmaceuticals | Upgrades: Outperform | n/a | $32.50 | - | 3 | Feb 15, 2019 | |
| ARRY Array Technologies | Initiates: Outperform | n/a | $12.34 | - | 3 | Jan 17, 2019 | |
| ABUS Arbutus Biopharma | Maintains: Market Perform | n/a | $2.73 | - | 1 | Nov 7, 2017 |
Deciphera Pharmaceuticals
Apr 30, 2024
Downgrades: Neutral
Price Target: n/a
Current: $25.27
Upside: -
Immunocore Holdings
Apr 23, 2024
Reiterates: Buy
Price Target: $92
Current: $59.08
Upside: +55.72%
Immunome
Apr 15, 2024
Initiates: Buy
Price Target: $35
Current: $14.06
Upside: +148.93%
ADC Therapeutics
Apr 5, 2024
Reiterates: Buy
Price Target: n/a
Current: $4.41
Upside: -
Immuneering
Mar 14, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.42
Upside: -
Mersana Therapeutics
Feb 29, 2024
Upgrades: Buy
Price Target: $7
Current: $3.17
Upside: +120.82%
BeiGene
Feb 27, 2024
Maintains: Buy
Price Target: $350 → $345
Current: $153.94
Upside: +124.11%
Allogene Therapeutics
Jan 5, 2024
Downgrades: Neutral
Price Target: n/a
Current: $2.76
Upside: -
Incyte
Dec 4, 2023
Upgrades: Buy
Price Target: n/a
Current: $52.05
Upside: -
Xencor
Nov 8, 2023
Maintains: Buy
Price Target: $40 → $34
Current: $20.94
Upside: +62.37%
Exelixis
Oct 11, 2023
Reiterates: Buy
Price Target: $30
Current: $23.46
Upside: +27.88%
Syndax Pharmaceuticals
Jul 25, 2023
Maintains: Buy
Price Target: $40 → $42
Current: $21.13
Upside: +98.77%
Adicet Bio
Jun 27, 2023
Downgrades: Neutral
Price Target: $20
Current: $1.49
Upside: +1,242.28%
Blueprint Medicines
May 23, 2023
Maintains: Buy
Price Target: $78 → $82
Current: $91.34
Upside: -10.23%
ORIC Pharmaceuticals
Mar 21, 2023
Downgrades: Neutral
Price Target: $15
Current: $8.83
Upside: +69.88%
Arvinas
Jan 12, 2023
Downgrades: Neutral
Price Target: n/a
Current: $31.77
Upside: -
Adaptimmune Therapeutics
Jan 3, 2023
Upgrades: Buy
Price Target: $5
Current: $1.19
Upside: +320.17%
Zentalis Pharmaceuticals
Nov 11, 2022
Maintains: Buy
Price Target: $55 → $28
Current: $11.06
Upside: +153.16%
Genmab
Jan 3, 2022
Downgrades: Neutral
Price Target: n/a
Current: $27.69
Upside: -
Erasca
Aug 10, 2021
Initiates: Buy
Price Target: n/a
Current: $2.01
Upside: -
Cellectis
Apr 28, 2021
Downgrades: Neutral
Price Target: n/a
Current: $2.56
Upside: -
Bolt Biotherapeutics
Mar 2, 2021
Initiates: Buy
Price Target: n/a
Current: $1.11
Upside: -
Revolution Medicines
Mar 9, 2020
Initiates: Buy
Price Target: n/a
Current: $37.28
Upside: -
bluebird bio
Mar 5, 2019
Downgrades: Market Perform
Price Target: n/a
Current: $0.89
Upside: -
Agios Pharmaceuticals
Feb 15, 2019
Upgrades: Outperform
Price Target: n/a
Current: $32.50
Upside: -
Array Technologies
Jan 17, 2019
Initiates: Outperform
Price Target: n/a
Current: $12.34
Upside: -
Arbutus Biopharma
Nov 7, 2017
Maintains: Market Perform
Price Target: n/a
Current: $2.73
Upside: -